I
nterleukin-4 is a pleiotropic cytokine that plays a central role in immunoregulation (for review, see Refs. 1 and 2). It is best known for its ability to induce selective Ig isotype switching in B lymphocytes and to promote the development of Ag-specific Th2 cells from naive CD4 ϩ precursors. In mice, strain-specific differences in the levels of IL-4 produced in infections such as Leishmania major and Schistosoma mansoni contribute to the variable Th2 response that influences disease course (3) (4) (5) (6) (7) (8) . However, IL-4 also has profound effects on the activation and/or growth of many other target cells, including endothelial cells, neutrophils, mast cells, eosinophils, and CD8 ϩ T cells. The dysregulation of IL-4 production has been linked to allergic disease and autoimmunity in both human and murine models, attesting to its importance (9, 10) . While most studies have focused on IL-4 production by select subsets of activated T lymphocytes, including Th2, ␥␦ ϩ , and NK1.1 ϩ cells (2, 11, 12) , mast cells also express IL-4 and are likely to provide a significant source of this cytokine in vivo (13, 14) . In addition to de novo inducible synthesis, mast cells contain stores of preformed IL-4 that are released immediately upon activation (15) . Mast cells are most prevalent at sites of Ag entry, such as the skin, respiratory tract, and gastrointestinal tract (16, 17) , where mast cell-derived IL-4 can initiate inflammatory reactions of the innate immune response. Activated mast cells can also migrate to local lymph nodes (18) . This observation supports the idea that mast cells can impact adaptive immune responses by localizing to sites of initial T cell activation and, through elaboration of cytokines such as IL-4, directly influence Th development.
IL-4 production by naive T cells is dependent on the delivery of at least two signals: cross-linkage of the TCR and costimulation through CD28 and/or CD40 ligand (19, 20) . In contrast, mast cells are activated through Fc receptor interactions with IgE or IgG (21, 22) , as well as via direct interactions with bacterial and parasite products, complement components, and neuropeptides such as Substance P (16, (23) (24) (25) (26) (27) . We previously hypothesized that the differences in the ligand-receptor interactions leading to IL-4 production in these cell types would be reflected in distinct nuclear signaling events. There is now substantial evidence to support this hypothesis. For example, GATA-3 and Maf, transcription factors that are essential for maximal IL-4 gene expression by Th2 cells (28, 29) , are not expressed in mast cells (30, 31) . Intact STAT6 signaling pathways are also required for Th2 differentiation (32) (33) (34) , yet mast cells exhibit STAT6-independent IL-4 production: bone marrow-derived mast cell precursors from STAT6 Ϫ/Ϫ mice can differentiate into mature cells that express IL-4 levels comparable to those of wild-type cells (35) . Finally, although IL-4 gene transcription is NF-AT-dependent in both mast cells and T cells, there is evidence that each cell type uses distinct NF-AT isoforms (36 -39) .
A transcriptional regulatory element located in the second intron of the IL-4 gene may also contribute to cell type-specific expression patterns (40, 41) . Several features of this element suggest that it is mast cell specific. Its location was defined by a DNase I hypersensitive site in chromatin examined from a variety of transformed and nontransformed mast cell lines but absent in EL-4 T cells. It exhibits mast cell-specific activity in enhancer-reporter assays, and sequences that contribute to its activity are the binding targets of factors selectively expressed in mast cells and not T cells. These factors include PU.1, an ets family member that is essential for mast cell development, and GATA-1 and -2. However, simultaneous mutation of both GATA and PU.1 binding sites reduces enhancer activity by ϳ50%, suggesting other regions also contribute to the enhancer activity.
In this study, we have further examined the molecular requirements for full enhancer activity of the intron regulatory element in murine mast cells. We demonstrate that a consensus STAT site that preferentially associates with STAT5 contributes to its enhancer activity in mast cells. We also provide evidence that the intron element plays a role in acquiring and/or maintaining the IL-4 gene locus in a demethylated state in IL-4-producing cells. An intact GATA binding site is essential for this function. Thus, analogous to the enhancer sequences identified in the intervening sequences of Ig and TCR genes, this element has a dual function: it acts as a transcriptional enhancer in transient transfection assays and also plays a role in conferring developmentally regulated demethylation to the IL-4 gene locus.
Materials and Methods

Cell lines
CFTL-15 is a nontransformed murine mast cell line derived from fetal liver and is IL-3 dependent (42) . These cells express low levels of IL-4 mRNA and protein constitutively and up-regulate this expression initiated in response to activation by cross-linking of the high affinity Fc⑀ receptor or calcium mobilization by treatment with ionomycin (14) . CFTL-15 cells were cultured in complete RPMI 1640 containing 10% FCS in the presence of 25% WEHI-3B cell supernatants as a source of IL-3. Bone marrowderived mast cells were derived from bone marrow taken from the femurs of 6-to 8-wk-old C57BL/6 mice and cultured under the same conditions as CFTL-15 mast cells except that recombinant murine stem cell factor (12.5 ng/ml; R&D Systems, Minneapolis, MN) was added during the first 2 wk of culture. In some experiments, ABFTL-3, a growth factor-independent Abelson murine leukemia virus-transformed murine mast cell line that expresses IL-4 constitutively, was used (13) . M12 B cells have been described previously (43) .
DNase I footprinting
In vitro DNA footprinting was conducted as described (44) . Briefly, 10 g of crude mast cell nuclear extracts were incubated with 0.5 ng (10,000 -15,000 cpm) of a 32 P-labeled DNA sequence corresponding to base pairs 353-554 of the 683-bp BglII fragment in the second intron of the IL-4 gene. Five nanograms of DNase I (Life Technologies) was added to the reaction, and the digestion was stopped after 60 min. A control reaction was conducted containing no nuclear extract. Following precipitation, the digested DNA fragments were resolved on a 6% denaturing polyacrylamide gel, and results were assessed by autoradiography. The final reaction conditions described above were determined by titrating concentrations of DNase I, protein, and competitor DNA, as well as varying digestion times. The sequence used in these experiments (bp 353-554) was amplified by PCR and subcloned into pGEM-3 (Promega, Madison, WI). The probe was prepared by linearizing pGEM-3 at the 3Ј or 5Ј end of the probe, dephosphorylating that end, and then cutting at the other end to release the fragment. The dephosphorylated end was labeled with [␥-32 P]ATP using T4 kinase. Sequence homology searches were performed using the Transfac database (Ref. 45 ; http://transfac.gbf.de/TRANSFAC/).
Reporter gene constructs
The murine IL-4 intron enhancer-reporter plasmid used in these studies was constructed by deleting a BglII/PstI fragment corresponding to base pairs 1-254 of the originally defined 683-bp enhancer in p-chloramphenicol acetyltransferase (CAT) 4 promoter (Promega) (41) . This subsequence corresponds to base pairs 255-683.
Site-directed mutagenesis
Mutations were introduced into the IL-4 intron/pCAT promoter reporter construct by oligonucleotide-directed mutagenesis using the either the Quick Change system (Stratagene, La Jolla, CA) or the Sculptor M13 kit (Amersham, Arlington Heights, IL; indicated by an asterisk). All mutations were verified by sequencing. The mutant forms of the oligonucleotides are as follows (altered nucleotides are underlined): m426, 415-446, 5Ј-GG  GAGGGGACTCGATCGACAGGCTGATAGTGC*; m475, 491-454,   5Ј-GCTATTGATACACCTGCAGCAAGTCATGTGTTTGTCA; m482,  498 -469, 5Ј-GCACAAAGCTACCTGCAGAGCATAGCCAAG; m491,  478 -511, 5Ј-GCTGTATCAATAGCGATCGACATTTCAGTTCCTG*; m  504,520 -490, 5Ј-CCATGAAAACAGGCCTGCAGATGCACAAAGC;  m514 (STAT), 495-433, 5Ј-GTGCATTTCAGTTCCTGTTGGCATG  GAAACACACCACTG*; m523, 508 -546, 5Ј-CCTGTTTTCATGGAAC  GATCGCACTGAGAATGAAAGGCC*; m531, 519 -548, 5Ј-GGAAA  CACACCATGGCCAATGAAAGGCCCC; m538, 528 -543, 5Ј-CCACTG  AGAAGAGTCGGCCCCAAAG; m545, 533-563, 5Ј-GAGAATGAAA  GGGTCGACCGTCTTGACTTAC; m553 , 543-568, 5Ј-GGCCCCAAAG CCCGAGCTTACCAGTG. Derivation of the reporter constructs containing the GATA and PU.1 mutations have been previously described (41) .
Transient transfections and CAT reporter gene assays
A total of 5 ϫ 10 6 CFTL-15 mast cells were transfected by electroporation (Bio-Rad Gene Pulser at 425V and 400 F; Richmond, CA) using 25 g of reporter plasmid. After 24 h, cells were divided into two aliquots, and one aliquot was stimulated with 1 g/ml ionomycin (Sigma). The cells were harvested 18 h poststimulation. Equal amounts of cell extracts were assayed for CAT activity using the scintillation diffusion assay as previously described (40) . In some experiments, CAT data were normalized to the relative expression of a cotransfected pSV-␤-galactosidase expression vector (Promega) to correct for variations in transfection efficiency.
EMSA
Nuclear extracts of CFTL-15 mast cells were prepared using the method described by Dignam et al. or Fiering et al. (46, 47) with high concentrations of protease inhibitors (Boehringer Mannheim, Indianapolis, IN). Protein concentrations of the nuclear extracts were determined with the BioRad protein assay kit. EMSAs were performed as previously described (38, 48) . Briefly, 5 g of crude nuclear extract was incubated with 0.1 ng (FP2, see below and Fig. 2A ) or 1 ng (intron enhancer STAT (iSTAT), see below and Fig. 2A ) 32 P-labeled oligonucleotide for 1 h. Binding reactions with the FP2 probe were performed in a buffer containing 10 mM Tris (pH 7.5), 45 mM KCl, 1 mM EDTA, 0.1% Triton X-100, 12.5% glycerol, 0.5 mM DTT, and 20 g/ml poly(dI-dC). Reactions with the iSTAT probe were conducted in 20 mM HEPES (pH 7.9), 40 mM KCl, 1 mM MgCl 2 , 0.1 mM EDTA, 4% Ficoll, 0.5 mM DTT, 1.2 mg/ml BSA, and 100 g/ml poly (dI-dC). The protein/DNA complexes were separated on a 5% polyacrylamide gel in a buffer consisting of 25 mM Tris, 190 mM glycine, and 1 mM EDTA (for FP2 EMSAs) or 10 mM Tris, 10 mM boric acid, and 2 mM EDTA (for STAT EMSAs). For all competition experiments, a 100-fold molar excess of unlabeled competitor oligonucleotide was used.
Oligonucleotide probe and competitor sequences
The following oligonucleotide probe and competitor sequences were used: intron enhancer STAT site probe (iSTAT), 5Ј-TGTTTTCATGGAAA CACA; FP2 region probe (FP2), 5Ј-CATGACTTGGCTATGCTGTAT CAATAGCTTTGTG; mutated intron enhancer STAT site (altered nucleotides are underlined) (miSTAT), 5Ј-TGTGGGCATGGAAACACA; ␤-casein IFN-␥ activation site element (GAS), 5Ј-AGATTTCTAGGAAT TCAAATC; IL-4 promoter STAT site -154 to -132 of the murine IL-4 5Ј region (48) (IL-4 STAT), 5Ј-TGATTTCACAGGAAAATT; consensus Pit 1, 5Ј-TGTCTTCCTGAATATGAATAAGAAATA; consensus Oct 1 (Oct), 5Ј-TGTCGAATGCAAATCACTAGAA; consensus AP-1, 5Ј-CGCTT GATGAGTCAGCCGGAA; FP2 m475 (m475), 5Ј-CATGACTTGCTG CAGGTGTATCAATAGCTTTGTG; FP2 m482 (m482), 5Ј-CATGACTT GGCTATGCTCTGCAGGTAGCTTTGTG.
Western blot analyses
Western blot analyses were performed essentially as described (44) . Proteins were separated on 10% SDS-PAGE gels and electro-blotted to nitrocellulose membrane (Schleicher and Schuell, Keene, NH). The membranes were blocked with 5% nonfat dry milk in 10 mM Tris (pH 8.0), 150 mM NaCl, and 0.5% Tween 20. Anti-Pit 1 and anti-NF-B Abs (rabbit polyclonal Ig) (Santa Cruz Biotechnology, Santa Cruz, CA) and anti-STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6 mouse mAbs (Zymed, San Francisco, CA) were used as the primary Ab at 1:1000 dilution. HRP-conjugated goat anti-rabbit secondary Ab (Amersham) was used at a 1:5000 dilution. The blots were visualized using the Renaissance Western blot chemiluminescence reagent (NEN, Boston, MA).
Oligonucleotide affinity precipitation
Large-scale (200 -500 fold) EMSA binding reactions were conducted using the indicated 5Ј biotinylated probe. The resulting protein/DNA complexes were precipitated with streptavidin-agarose (Sigma, St. Louis, MO) and washed extensively with binding buffer. The specifically bound proteins were eluted with SDS-PAGE loading dye and separated on a 10% SDS-PAGE gel. The presence of specific proteins was visualized by Western blot analysis as described above.
Stable cell transfections
Two versions of an IL-4 genomic construct, with (gIL-4) and without (g⌬IL-4) the intron enhancer sequences, were stably transfected into CFTL-15 mast cells and M12 B cells together with pEGFP-N1, a green fluorescent protein (GFP)/neomycin-resistance gene expression vector (Clontech, Palo Alto, CA) at a 10:1 ratio using a Bio-Rad Gene Pulser at 425 V and 400 F. The wild-type construct contains the complete IL-4 genomic sequence (gIL-4) from 797 bp 5Ј of the transcriptional start site to ϳ2000 bp 3Ј of the fourth exon. It was made by ligating the HindIII fragment of the IL-4 genomic clone, pMIL-5 (49), which contains exons I, II, and III, with a HindIII fragment from pMIL-1 (49) into pUC18. The enhancerless version of this construct was assembled from PCR-generated fragments that lack the 683-bp BglII intron enhancer element. Mutations in the GATA, ets, FP2 (m482), and STAT sites were made in the context of pMIL-5 (48), a construct containing exons I, II, and III using the Quik Change mutagenesis system (Stratagene). After transfection, the cells were cultured in medium containing 400 -600 g/ml G418 for at least 4 wk. Cells were cloned by limiting dilution. Integration of the transfected plasmids was monitored by flow cytometry and by PCR using genomic DNA as a template and vector-and IL-4 exon-specific primers.
Determination of the methylation status of the IL-4 gene locus
Genomic DNA was isolated from stably transfected and untransfected cells with DNAzol (Life Technologies, Rockville, MD) using the manufacturer's suggested protocol. DNA was digested with HindIII followed by digestion with either MspI (methylation insensitive) or HpaII (methylation sensitive) (Life Technologies). The digested DNA was separated on a 1% agarose-TBE gel and transferred to nitrocellulose membrane by the Southern blot protocol as described (44) . The blot was probed with a 32 P-radiolabeled StuI/EcoRI fragment from the second intron of IL-4 (see Fig. 5A ).
Results
In vitro footprinting reveals three regions of protein binding within the IL-4 intron enhancer
Previous analyses of the sequences that comprise the IL-4 gene intron enhancer demonstrated that at least two elements, corresponding to consensus PU.1 (ets) and GATA binding sites, contribute to the enhancer's activity (41) . Because the simultaneous mutation of both these sites does not completely eliminate enhancer activity, it is likely that additional regions are involved. As a first step toward defining such potential sites, in vitro footprinting experiments were performed using mast cell nuclear extracts and a DNA probe comprising a 428-bp intron sequence. This probe (base pairs 255-683 of the 683-bp BglII fragment, see Fig. 1A ) corresponds to a sequence that confers full enhancer activity in reporter construct assays (41) . These assays revealed protein binding to three distinct regions, termed FP1, FP2, and FP3 ( Fig. 1, B-D) . FP1 encompasses a previously defined SP-1 site and the GATA binding site, while FP3 is adjacent to the PU.1 site ( Fig. 2A) . However, the sequences within FP2 and FP3 have not been previously analyzed for regulatory activity.
Additional sequences contribute to IL-4 enhancer activity
To examine the ability of sequences within FP1, FP2, and FP3 to confer enhancer activity, mutations were introduced into sequences that span the three footprinted regions of the intron sequence within the context of a CAT reporter construct ( Fig. 2A) . Transient transfection assays were performed in CFTL-15 mast cells to assess the consequence of these mutations on enhancer activity. As shown in Fig. 2B , the mutations designated m482, within FP2, and m514, within FP3, had the most profound effect on enhancer activity. Each mutation alone caused an 80% reduction in CAT activity relative to the wild-type levels. A transcription factor binding site homology search using the Transfac database (45) revealed that the m482 mutation alters a site resembling a consensus Pit 1 binding site. The mutation m514 disrupts a consensus STAT binding site (50, 51) .
The site defined by m482 within FP2 forms specific DNA-protein complexes in mast cells
Specific DNA-protein interactions at regions defined by footprint analysis were first assessed by EMSA using an oligonucleotide probe corresponding to sequences in the FP2 region. A single complex forms using both unstimulated (data not shown) and stimulated CFTL15 nuclear extracts (Fig. 3A) . Competition experiments with mutant forms of unlabeled FP2 demonstrate that the sequences defined by m482, but not m475, contribute to mast cell protein binding.
A protein antigenically related to Pit 1 is expressed in mast cells
Based on computer analyses (45), m482 disrupts a site resembling a Pit 1 binding site. Pit 1 was originally described as a pituitaryspecific protein belonging to the POU domain family of transcription factors (52) . Of potential interest is the finding that Pit 1 specifically interacts with another IL-4 intron binding protein, GATA-2, to regulate development of distinct pituitary cell types (53) . Its expression in mast cells has not been previously evaluated. Western blot analysis of CFTL-15 and bone marrow-derived mast cell nuclear extracts was performed using commercially available anti-Pit 1 Abs. The results indicate that a protein of 38 The numbering of mutations corresponds to the first disrupted base pair for each mutation in the 683-bp BglII fragment within the second intron. Mutations are indicated by gray boxes, consensus transcription factor binding sites are designated with light brackets, and footprinted regions (FP1-3) are indicated with heavy brackets. The sequences corresponding to the probe used for STAT binding analyses are also shown (iSTAT). B, CFTL-15 mast cells were transfected with equimolar amounts of the indicated IL-4 intron enhancer constructs. After an overnight incubation, cultures were stimulated with ionomycin, harvested 48 h posttransfection, and assayed for CAT activity as previously described (40) . The data are compiled from at least four independent transfection experiments in which the wild-type control data was considered 100% activity. The activity of other plasmids is expressed relative to the wild-type activity. Error bars represent SD. In some experiments, the IL-4 reporter constructs were cotransfected with a ␤-galactosidase expression construct (85) allowing normalization of the CAT activity to the transfection efficiency of each electroporation as previously described (40) . kDa, the reported molecular mass of Pit 1, is expressed constitutively in both mast cell lines but not in M12 B cells (Fig. 3B ) or T cells (data not shown).
Pit 1 does not associate with the intron enhancer element
The apparent constitutive and selective expression of this transcription factor in mast cells, together with protein binding to the Pit 1-like sequence in the FP2 region, suggests that Pit 1 may contribute to the activity of this element. To examine the possible involvement of Pit 1 in the FP2 complex, several experiments were performed. A Pit 1 consensus site oligonucleotide was used as a probe in EMSA experiments. Proteins in mast cell nuclear extracts form specific complexes with oligonucleotides containing the Pit 1 binding site (Fig. 3C) . Of note, these complexes migrate with a distinct mobility compared with the FP2 complexes. Unlabeled oligonucleotides corresponding to the Pit 1 sequence or to an Oct 1 binding sequence compete for protein binding in competition experiments. However, protein binding to this sequence is not competed by a 100-fold molar excess of FP2 oligonucleotides. Likewise, competitor Pit 1 and Oct 1 consensus oligonucleotides do not disrupt FP2 DNA-protein complexes (data not shown). Neither the Pit 1 nor the FP2 protein-DNA complex were supershifted by the commercially available Pit 1 antisera (data not shown).
Oligonucleotide affinity precipitation assays were also performed. Large-scale binding reactions were performed using mast cell nuclear extracts and a biotinylated FP2 probe. DNA-protein complexes were precipitated with streptavidin-agarose beads. After extensive washing, specifically bound proteins were eluted and subjected to Western blot analysis using Pit 1 antisera. As shown in Fig. 3D , there is no evidence that anti-Pit 1-reactive proteins are specifically eluted from the FP2 probe. These data indicate that despite the strong constitutive expression of this protein in mast cells, Pit 1 does not associate with this IL-4 gene regulatory site.
We speculate that a related, "Pit 1-like" factor, perhaps another member of the POU domain family, binds to this site in vivo.
STAT proteins bind the intron STAT element in mast cells
The functional region defined by m514 flanks the previously defined PU.1 binding site and directly disrupts a STAT consensus site (TTTCATGGAA) that could potentially bind either STAT6 (TTN 6 AA) or other STAT family members (TTN 5 AA) (50, 51) . We first asked if this site could function as a bona fide STAT6 binding site. Extracts from IL-4-stimulated B cells were used in EMSA binding reactions with probes derived from the FP3 region, designated iSTAT ( Fig. 2A) . Two complexes are observed, both of which are competed by "self" (lane 2) but not by the unrelated AP-1 oligonucleotides (lane 4). A conventional STAT6 oligonucleotide corresponding to sequences present in the murine IL-4 promoter competes for proteins binding to the slower mobility complex (lane 3). STAT6-specific antisera can also supershift this complex (lane 5). These data indicate that STAT6 as well as other factors can bind to the iSTAT binding site. Similar experiments were conducted with extracts from unstimulated and IL-4-or ionomycin-stimulated mast cells. As shown in Fig. 4B, IL-4 induces the association of a single complex (lane 2). This complex contains a mast cell-specific isoform of STAT6 that lacks the C-terminal amino acids and fails to react with antisera that can supershift STAT6 in B and T cells (48) . EMSA experiments with ionomycinstimulated mast cell extracts reveal that several activation-dependent DNA-protein complexes form with the iSTAT probe (lane 3). Notably, the number and mobility of complexes formed with ionomycin-activated mast cell extracts are distinct when compared with the IL-4-induced complex.
The specificity of the ionomycin-inducible protein-DNA interactions is demonstrated in cold competition experiments (Fig. 4C) . Competition with a 100-fold molar excess of unlabeled iSTAT 
A, EMSAs were performed with nuclear extracts isolated from ionomycin-stimulated CFTL-15 mast cells and the FP2 DNA probe. Where indicated, a 100-fold molar excess of unlabeled wild-type (self), mutated (m482 and m475), or unrelated (UR) competitor (an AP-1 consensus site) oligonucleotide was added to the standard binding reaction mixture. B, Pit-1 expression in mast cells. One hundred micrograms of crude nuclear extract from unstimulated M12 B cells, CFTL-15, or bone marrow-derived mast cells (BMMC) was analyzed by Western blot techniques using ␣-Pit-1 antisera. C, The binding of mast cell nuclear proteins to a consensus Pit 1 binding site was assayed using EMSA analysis. Where indicated, a 100-fold molar excess of unlabeled wild-type (self), mutated (m482 and m475), Oct binding site, or unrelated (UR) competitor (an AP-1 consensus site) oligonucleotide was added to the standard binding reaction mixture. D, Analysis of Pit 1 binding to FP2 sequences using DNA oligonucleotide affinity precipitation. Biotinylated oligonucleotides corresponding to the FP2 region of protein binding were incubated with crude CFTL-15 mast cell extract under the same binding conditions used for the EMSA experiments. After precipitation with streptavidin-agarose beads, the bound proteins were analyzed by Western blot with antiPit-1 antisera. Crude extracts and unbound fractions were also analyzed.
probe (self, lane 2), but not an unrelated probe (AP-1, lane 6), completely eliminated the detection of the complexes. These experiments also indicate that only the faster mobility complex contains proteins related to the STAT family of transcription factors. Competition with an unlabeled oligonucleotide containing a disruption in this STAT site (miSTAT (XXCATGAA), lane 3) fails to compete for proteins associated with the fast mobility complex but eliminates detection of the upper complexes. Surprisingly, while a ␤-casein probe (GAS, lane 5), which can bind all STAT family members, competes solely for binding of this fast mobility complex, a consensus STAT6 (lane 4) probe competes poorly. These results indicate that ionomycin stimulation of mast cells, which can also activate STAT6 (48), does not result in STAT6 binding to this region. Rather, activation induces the formation of complexes that contain other STAT family members as well as factors unrelated to STAT.
The intron STAT site specifically binds STAT5a and STAT5b
Ionomycin induces the expression of both IL-3 and IL-4 in mast cells, which may in turn act in an autocrine fashion to activate STAT5 and STAT6, respectively, in these cells. To determine whether STAT5 binds to the iSTAT site in stimulated mast cells, DNA oligonucleotide affinity precipitation reactions were conducted as described above using a biotinylated version of the iSTAT probe. Both STAT5a-and STAT5b-specific Abs reacted with the bound protein fraction (Fig. 4D) . In contrast, a STAT6 Ab showed only weak reactivity. Abs to STATs 1-4 and NF-B failed to react with the bound protein fraction. Thus, STAT5a and 5b FIGURE 4. STAT5 preferentially binds to the IL-4 gene intron regulatory element. A, STAT6 can associate with the iSTAT element. Whole-cell extracts from IL-4-stimulated M12 B cells were used in EMSA experiments with a radiolabeled iSTAT probe (see Fig. 2A ). Where indicated, a 100-fold molar excess of unlabeled wild-type (self), a defined STAT6 binding site, an AP-1 consensus site oligonucleotide, or anti-STAT6 Ab was added to the standard binding reaction mixture. Ø indicates no competitor is added. Arrows denote migration position of the STAT6-containing complex (filled) and supershifted with an anti-STAT6 Ab (open). B, IL-4 and ionomycin induce distinct protein-DNA complexes with the iSTAT probe. EMSA reactions were performed with whole-cell extracts from unstimulated (Ø), IL-4-treated, or ionomycin (I)-stimulated mast cells. Arrows denote three distinct ionomycin-induced complexes. C, EMSA analysis of protein-DNA interactions with the IL-4 gene iSTAT site. Binding reactions were performed with the iSTAT oligonucleotide probe and ionomycin-activated mast cell nuclear extracts. To examine the specificity of the various complexes, competition experiments were conducted using a 100-fold molar excess of the indicated unlabeled oligonucleotide added to the standard EMSA binding reaction. The filled arrow indicates the complex containing the putative STAT proteins. D, STAT5 binding to the enhancer in mast cells. DNA oligonucleotide affinity precipitations were performed with a biotinylated iSTAT probe and whole-cell CFTL-15 mast cell extracts. The specifically bound proteins were analyzed by western blot using anti-STAT1, anti-STAT2, anti-STAT3, anti-STAT4, anti-STAT5a, anti-STAT5b, anti-STAT6 murine mAbs, or purified rabbit anti-NF-␤ polyclonal Ab.
constitute the major components of the faster migrating inducible mast cell iSTAT complex.
The intron regulatory element influences the methylation state of the IL-4 gene in murine mast cells
Several cell type-restricted regulatory elements have been identified in the intervening sequences of both the Ig and TCR genes (for review see Refs. 54 and 55). Originally defined as conventional enhancer sequences in reporter assays, they appear to have an additional function in vivo. They have a major influence on chromatin accessibility of these loci. For example, deletion of the or Ig enhancer element in the context of a stably transfected recombination substrate results in a loss of the ability to undergo recombination and methylation of the introduced sequences in appropriate cell types, indicative of an inaccessible chromatin configuration (56, 57) .
Based on this paradigm, we asked whether the defined mast cell intron enhancer could also influence chromatin accessibility of the IL-4 gene. It is well established that methylated cytosines within chromosomal DNA are associated with gene inactivation, whereas demethylated regions correlate with transcriptionally active or inducible genes (58, 59) . However, until recently, the relationship of DNA methylation state to the conventional markers of chromatin accessibility such as DNase I hypersensitivity and local histone acetylation has been less clear. The recent discovery of MeCp2, a protein that binds methylated CpG dinucleotides and recruits deacetylase activity to specific chromosomal regions, provides a direct link between methylation of DNA and histone deacetylation and, therefore, chromatin accessibility (60, 61) . Thus, we asked whether the methylation state of integrated IL-4 gene contructs is influenced by the intron regulatory element. Two versions of an IL-4 genomic construct, with (gIL-4) and without (g⌬IL-4) the intron enhancer sequences (Fig. 5A) , were stably transfected into CFTL-15 mast cells and M12 B cells, a non-IL-4-producing cell line, along with a GFP/neomycin-resistance gene expression vector. After at least 4 wk of selection in G418, genomic DNA was isolated from each transfectant culture.
We first verified that the appropriate constructs were integrated in each cell population using PCR. Primers that hybridize to pUC18 vector sequences 5Ј of the IL-4 gene cloning site as well as to sequences just 3Ј of the intron element were used to amplify the transfected IL-4 gene sequences (Fig. 5A ). As shown in Fig. 5B , DNA from cells transfected with either the wild-type IL-4 construct or the deleted IL-4 construct but not those transfected with the GFP/neomycin vector alone served as successful templates and yielded a PCR product of the expected size. These data confirm that the wild-type and enhancerless IL-4 genomic constructs are stably integrated into both M12 B cells and CFTL-15 mast cells.
To assess the chromatin state, the methylation status of the transfected sequences was then examined by Southern blot analysis using a pair of enzymes whose recognition site is CCGG: HpaII, which is sensitive to methylated CpGs, and MspI, which cuts irrespective of the methylation state. Our hypothesis predicts that both the transfected wild-type and enhancerless genes will be methylated in non-IL-4-producing cells, but only the deleted construct will be methylated in IL-4-producing mast cells. As expected, both versions of the transfected IL-4 gene constructs are methylated in M12 cells (Fig. 5C, lanes 6 and 9, left) , as is the endogenous gene, reflecting the inactivity of the IL-4 gene in B cells. The wild-type construct is demethylated in bulk cultures of transfected CFTL-15 mast cells (Fig. 5C, lane 6, right) . In contrast, the integrated, enhancerless construct is methylated in IL-4-producing cells (as indicated by its resistance to HpaII digestion, Fig.  5C , lane 9, right), despite the demethylated state of the endogenous IL-4 locus. We speculate that the relatively light intensity of the HpaII-resistant band reflects the fact that fewer cells in the bulk-transfected culture contain the integrated transgene, whereas all contain the endogenous IL-4 gene. Using a probe corresponding to Ϫ800 to ϩ60 of the IL-4 gene with the same DNA samples, we confirmed that demethylation of the two upstream HpaII sites present in the transfected construct (at ϳ749 and between intron I and II, see Fig. 5A ) is likewise dependent on the presence of the intron regulatory element (data not shown).
Individual clones were also isolated from mast cell transfectants using limiting dilution cloning techniques. The analyses of two clones of each type of transfectant are presented in Fig. 6, A and B , and are representative of our analysis of at least four clones of each type. As shown in Fig. 6A , PCR analyses confirmed the appropriate IL-4 gene constructs are integrated into these clonal populations. In addition, the methylation status of the transfected constructs was identical with that observed in the bulk CFTL-15 mast cell cultures (Fig. 6B) . The integrated enhancerless construct is resistant to HpaII digestion (lanes 15 and 18) in g⌬IL-4-transfectant clones, indicating a failure to become demethylated. It is notable that the intensity of the HpaII-resistant band is much stronger than that observed in experiments with the bulk-transfected cells, which likely reflects the higher proportion of cells containing the integrated transgene in these cloned lines. Taken together, these results strongly support the hypothesis that the intron sequences have an important role in regulating cell type-specific accessibility of the IL-4 gene in murine mast cells by influencing the methylation status of the locus.
Mutations in the intron GATA binding sites interfere with the ability to acquire and/or maintain a demethylated locus
We next asked whether the functionally important sites defined in enhancer assays could contribute to the ability of the intron element to influence IL-4 gene methylation status. Southern blot analyses were performed as described above using DNA isolated from cells stably transfected with IL-4 genomic constructs (see Fig. 7A ) containing mutations in the GATA, ets, and STAT sites as well as the site defined by m482. PCRs with vector-and gene-specific primers were conducted to confirm integration of the constructs in transfected cells (Fig. 7B) . As shown in Fig. 7C , DNA from the mGATA transfectants was unable to achieve a completely demethylated state as shown by its partial resistance to HpaII (lane 9).
The same results were obtained in several independent experiments even under conditions in which the DNA samples were subjected to multiple treatments of excess enzyme to assure that complete digestion occurred. The STAT and ets site mutations, but not m482, also reproducibly resulted in decreased demethylation at some sites within the intron region of the transgene; however, the effect was less marked than that observed in the mutant GATA transfectants. Thus, association of GATA, and perhaps to a lesser extent STAT and PU.1, with an element in the second intron of the mouse IL-4 gene influences its methylation state.
Discussion
While most previous studies have focused on the cis-and transacting factors that initiate IL-4 gene transcription in activated cells, there is clearly an additional level of regulation. Studies in T cells (62, 63) In this study, we provide evidence that the regulatory element defined within the second intron of the murine IL-4 gene plays a role in both these processes in mast cells. First, it functions as a position-and orientation-independent transcriptional enhancer in conventional reporter gene assays and can act with both the native IL-4 gene promoter as well as heterologous promoters (40) . Enhancer activity is dependent on sequences forming binding sites for GATA-1 and GATA-2, PU.1, STAT5, and a Pit 1-related factor. Second, this element appears to play a role in mediating or maintaining locus opening. Both the endogenous IL-4 gene and a stably transfected wild-type IL-4 chromosomal gene construct are appropriately demethylated in IL-4-producing mast cells, indicative of an open locus. However, in IL-4-producing mast cells, the methylated state of a transfected construct lacking the intron regulatory element strongly suggests that these sequences are necessary to achieve and/or maintain an accessible chromatin configuration. The dependence on cell type-specific factors for this effect is demonstrated by the inability of either construct to exhibit a demethylated state in B cells.
This proposed "dual-function" element located within an IL-4 gene intron has many parallels to elements that influence developmentally regulated TCR and Ig gene expression in T and B lymphocytes (54, 55) . Several studies of the TCR ␣, ␤, and ␦ genes, as well as Ig heavy and light chain genes, demonstrate that sequences defined as enhancers in transient transfection assays also influence processes such as VDJ and VJ recombination as well as somatic mutation of the Ig genes. It is likely that these elements act to influence chromatin accessibility that allows the recombination machinery access to the region. In support of this idea, in vivo and in vitro studies of the -and -chain enhancers confirm their role in demethylation of the Ig locus. For example, a transfected -chain gene containing the intron heavy chain enhancer is hypomethylated in pre-B cells, correlating with expression of the heavy chain gene. Deletion of the enhancer leads to transcriptional inactivation and de novo methylation (64) . Similar types of analyses have shown that the light chain enhancer also has a role in inducing demethylation of the locus in a lineage-and developmental stage-specific manner (65, 66) . Genetic deletion of the TCR ␣ and ␤ enhancers also negatively affects recombination (67) (68) (69) . The apparent commonality of mechanisms that operate on such diverse gene systems such as the Ig, TCR, and IL-4 genes to regulate accessibility suggests that similar regulatory events occur at other gene loci. Indeed, these data may necessitate the development of a new paradigm for the in vivo function of many other gene regulatory elements, first defined as transcriptional enhancers, located in introns or elsewhere.
Our analysis of specific sites and proteins that associate with the intron element and mediate its activity also supports the idea that this element has dual function. Although little is known about the mechanisms through which enhancers act to influence locus opening, it is striking that many of the factors that associate with the functional elements of the IL-4 enhancer have been implicated in influencing chromatin accessibility at loci encoding other cell type-specific genes. These include GATA-1, PU.1, STAT5, and POU domain family factors. For example, it has been shown that GATA-1, expressed in myeloid lineage cells, is able to bind to GATA binding sites in nucleosomal DNA and cause extensive and cooperative breakage of the DNA/histone contacts (70) . Thus, this factor likely plays an important role in initiating locus-opening events. PU.1, a factor whose expression is limited to B cells, macrophages, neutrophils, and mast cells (41, (71) (72) (73) , can bind to plasmids containing the enhancer (71, 74) . Binding by PU.1 does not alter the nucleosomal array that assembles around the transfected plasmid, but does increase the restriction enzyme accessibility within the enhancer (74) . In addition, ectopically expressed PU.1 cooperates with other ets family members to induce I transcription, a marker of locus opening that precedes VDJ recombination, and to increase chromatin sensitivity to restriction enzyme digestion in stably transfected NIH 3T3 and pro-T cells. Finally, it has been established that STAT family members can interact with transcriptional coactivators such as CBP/p300 and PCAF, proteins that express intrinsic histone acetyltransferase activity (75) (76) (77) (78) (79) . Local histone acetylation is also associated with gene transcriptional activity and is another marker of accessible chromatin (80, 81) . It has been proposed that through their interaction with these coactivators, transcription factors direct this histone acetyltransferase activity to specific gene regulatory regions. STAT5, in particular, activated through IL-7 signaling, can interact with p300/CBP through an adapter protein termed Nmi (77) and has been shown to lanes 3, 6, and 9 ). Blots were probed with a 32 P-labeled StuI-EcoRI fragment from the second intron of IL-4 (see A above). WT designates DNA from cells that were transfected with the wild-type IL-4 gene construct.
regulate the accessibility of the TCR␥ locus (82, 83) . The established roles for these IL-4 intron binding factors in chromatin opening is consistent with the idea that they play similar roles in modifying IL-4 gene chromatin in IL-4-producing cells.
It is still unclear whether the intron element mediates mast cellspecific effects on IL-4 gene expression. GATA-1/2, Pit 1, and PU.1 are not expressed in T cells, and we have been unable to demonstrate conventional enhancer activity in Th2-derived cell lines (J. Hural and M. A. Brown, manuscript in preparation), supporting the idea that this element acts as a mast cell-specific enhancer. However, this intron region is also demethylated during the course of T cell differentiation (63) , and Agarwal and Rao recently demonstrated that the appearance of intron DNase I hypersensitive sites are associated with the development of an IL-4-producing phenotype in Th2 cells (62) . Of note, these sites appear to be in close proximity to, but spatially distinct from, those identified in mast cells. These findings raise the possibility that despite its lack of enhancer activity, the second intron is essential for regulating IL-4 transcription in both cell lineages. In T cells, it may only be involved in processes that mediate chromatin remodeling. Just as there are distinct cell type-specific factors that regulate transcriptional activation of the IL-4 gene, different developmental pathways leading to mast cell vs T cell development may necessitate the use of distinct subsets of factors and sites for locus opening. Related, but distinct factors that impact Th2 development, such as GATA-3 and STAT6 (28, 34) , may act on this element in T cells and serve such a function. This possibility is currently being examined.
Many questions remain regarding the relative in vivo contribution of this enhancer element and its associated trans-acting factors in directing transcriptional enhancement vs induction and/or maintenance of locus accessibility. Because these elements are generally defined in transient transfection assays where the native chromosomal context of a sequence is not preserved, we cannot exclude the possibility that it does not act in direct transcriptional enhancement in vivo. The observed enhancer activity in such assays may merely be a marker of its influence on transcription but is unrelated to its physiologic role. However, if the intron does mediate both functions in mast cells, determining whether the same set of transcription factors mediates both effects will be of great interest. The range of influence that the intron regulatory element exerts on the accessibility of the entire IL-4 gene locus is also undefined. It will be important to determine whether the intron element exerts only a local influence or also regulates the accessibility of distal sequences, such as those comprising the IL-13/ IL-4 intergenic region. This region is postulated to play a role in coordinately regulating the expression of cytokine genes that are linked on chromosome 11 in mice and chromosome 5 in humans (84) . Future studies using transgenic mice as well as those with targeted deletions in genes encoding the implicated factors will address these issues.
